Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept fat gene expression study in overweight and obese rheumatoid arthritis
2015-000089-72Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in rheumatoid arthritis (RA), sponsored by Policlinico Gemelli. Primary endpoint: Change in adipose tissue and immune cell gene expression at 6 months. Started Feb 2015; status: terminated.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-000089-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000089-72.